Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine is a synthetic small molecule belonging to the class of quinazoline-2,4-diamine derivatives. While specific information on this exact compound is limited, related quinazoline-2,4-diamine derivatives have been investigated as p21-activated kinase 4 (PAK4) inhibitors. These compounds have demonstrated potent inhibitory activity against PAK4 and antiproliferative effects in cancer cell lines, such as A549 lung cancer cells, suggesting potential as an anticancer agent. The mechanism of action involves the inhibition of PAK4, a kinase implicated in cell proliferation, migration, and invasion in various cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine.